Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
Launched by RAPHAS · Aug 31, 2022
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 19 - 65years with allergic rhinitis caused by the house dust mite antigen.
- • ImmunoCAP® titer \> 3.49 kUA/L for the house dust mite antigen.
- • Determined to be suitable for clinical trials as a result of laboratory tests.
- Exclusion Criteria:
- • Patients with uncontrolled, severe, or moderate asthma according to the Global Initiative for Asthma (GINA) guidelines.
- • In case of lactation or pregnancy.
- • If an infectious disease that may affect this study is identified.
- • Patients with a history of rhinology surgery within 6 months prior to the first administration of the clinical investigational drug.
- • If the allergy skin prick test is negative for the house dust mite antigen.
About Raphas
Raphas is an innovative clinical trial sponsor dedicated to advancing healthcare through the development and oversight of cutting-edge therapeutic solutions. With a focus on leveraging advanced technologies and rigorous scientific methodologies, Raphas collaborates with research institutions and healthcare professionals to design and execute clinical trials that prioritize patient safety and efficacy. Committed to transparency and ethical practices, Raphas aims to expedite the delivery of new treatments to market, ultimately improving patient outcomes and enriching the therapeutic landscape across various medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials